The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Background: Breast cancer exhibits significant molecular, pathological, and clinical heterogeneity. Current clinicopathological evaluation is imperfect for predicting outcome, which results in overtreatment for many patients, and for others, leads to death from recurrent disease. Therefore, additional criteria are needed to better personalize care and maximize treatment effectiveness and survival. Methods: To address these challenges, the Sweden Cancerome Analysis Network - Breast (SCAN-B) consortium was initiated in 2010 as a multicenter prospective study with longsighted aims to analyze breast cancers with next-generation genomic technologies for translational research in a population-based manner and integrated with healthcare; decipher fundamental tumor biology from these analyses; utilize genomic data to develop and validate new clinically-actionable biomarker assays; and establish real-time clinical implementation of molecular diagnostic, prognostic, and predictive tests. In the first phase, we focus on molecular profiling by next-generation RNA-sequencing on the Illumina platform. Results: In the first 3 years from 30 August 2010 through 31 August 2013, we have consented and enrolled 3,979 patients with primary breast cancer at the seven hospital sites in South Sweden, representing approximately 85% of eligible patients in the catchment area. Preoperative blood samples have been collected for 3,942 (99%) patients and primary tumor specimens collected for 2,929 (74%) patients. Herein we describe the study infrastructure and protocols and present initial proof of concept results from prospective RNA sequencing including tumor molecular subtyping and detection of driver gene mutations. Prospective patient enrollment is ongoing. Conclusions: We demonstrate that large-scale population-based collection and RNA-sequencing analysis of breast cancer is feasible. The SCAN-B Initiative should significantly reduce the time to discovery, validation, and clinical implementation of novel molecular diagnostic and predictive tests. We welcome the participation of additional comprehensive cancer treatment centers. Trial registration: ClinicalTrials.gov identifier NCT02306096.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SCAN-B fresh-tissue procurement is fully-integrated into routine clinical diagnostics across participating healthcare institutions5.”
From Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study (2019) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“340 of these patients were enrolled in the SCAN-B study5,33,34 (ClinicalTrials.gov ID NCT02306096), which is a prospective, observational, population-based cohort study, from which 254 with concurrent RNAseq were selected for extensive clinical review and WGS.”
From Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study (2019) · cites this paper as [5]
In the citing paper
“The Sweden Cancerome Analysis Network – Breast (SCAN-B; ClinicalTrials.gov identifier NCT02306096)5 is an on-going population-based observational study currently involving nine hospitals in the South of Sweden serving nearly two million inhabitants or ~20% of the Swedish population.”
From Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 1×
“Each data set is filtered to remove reads that align (using Bowtie 2 [26] with default parameters except -k 1 –phred33 –local) to ribosomal RNA/DNA (GenBank loci NR_023363.”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“Variant calls were annotated using ANNOVAR [41] with the databases refGene, snp137NonFlagged, and cosmic65 from the ANNOVAR website; additional databases of SNVs and indels were created, tcgaBreast using data from the Level 2.”
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 2×
“The remaining reads are aligned using TopHat2 [27] to the human genome reference GRCh37/ hg19 (with b37 masked chromosome Y and hs37d5 decoy sequences) together with 80,884 transcript annotations from the UCSC knownGenes table (downloaded 10 September 2012).”
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116 · cited 1×
“1 [28] is used to calculate expression levels, fragments per kilobase of exon per million mapped reads (FPKM), using default settings except –frag-biascorrect –multi-read-correct –library-type fr-firststrand –compatible-hits-norm.”
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 1×
“However, these assays are expensive (approximately €3,000 per test), and due to the fact that they were developed based on relatively small study populations (MammaPrint: 78 patients) [8] or only one subgroup of the disease (OncotypeDX: patients with estrogen-receptor-positive tumors with no involved lymph nodes and t…”
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277 · cited 1×
“However, these assays are expensive (approximately €3,000 per test), and due to the fact that they were developed based on relatively small study populations (MammaPrint: 78 patients) [8] or only one subgroup of the disease (OncotypeDX: patients with estrogen-receptor-positive tumors with no involved lymph nodes and t…”
Research works printed but not linked: 1
- Gene Expression Omnibus. Available at: http://www.ncbi.nlm.nih.gov/geo/.
Cited by
Bartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M., Madsen, C. D., Lindgren, D., Pekar, G., Karlsson, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07582-3 · Cited by 826
Self-citationLauss, M., Donia, M., Harbst, K., Andersen, R., Mitra, S., Rosengren, F., Salim, M., Vallon-Christersson, J., Törngren, T., Kvist, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01460-0 · Cited by 470
Self-citationWhole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reuterswärd, C., Häkkinen, J., Degasperi, A., Amarante, T. D., Saal, L. H., Hegardt, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0582-4 · Cited by 307
Self-citationBrueffer, C., Vallon-Christersson, J., Grabau, D., Ehinger, A., Häkkinen, J., Hegardt, C., Malina, J., Chen, Y., Bendahl, P.-O., Manjer, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00135 · Cited by 218
Self-citationbc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses
Jézéquel, P., Gouraud, W., Ben Azzouz, F., Guérin-Charbonnel, C., Juin, P. P., Lasla, H., & Campone, M. (2021) · Database · doi:10.1093/database/baab007 · Cited by 209
“In addition, we collected the log2(FPKM+0.1) data set provided by authors and available from the NCBI Gene Expression Omnibus (GSE81538 and GSE96058) (16).”
Influential
Metadata
- Authors
- Saal, L. H., Vallon-Christersson, J., Häkkinen, J., Hegardt, C., Grabau, D., Winter, C., Brueffer, C., Tang, M.-H. E., Reuterswärd, C., Schulz, R., Karlsson, A., Ehinger, A., Malina, J., Manjer, J., Malmberg, M., Larsson, C., Rydén, L., Loman, N., & Borg, Å.
- Affiliations
- Lund University (SE)
- Skåne University Hospital (SE)
- Corresponding author
- Borg, Åke
- ORCID
- Venue
- Genome Medicine
- Published
- 2015-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 20-20
- ISSN
- 1756-994X (ISSN-L)
- PMC
- PMC4341872
- OpenAlex
- W2115528316
- Cited by
- 255
- References
- 46
- Citations by year
- 2026: 28 · 2025: 39 · 2024: 54 · 2023: 36 · 2022: 18 · 2021: 28 · 2020: 16 · 2019: 8 · 2018: 7 · 2017: 8 · 2016: 12 · 2015: 1
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Genome Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- Stiftelsen för Strategisk Forskning
- VINNOVA
- Cancerfonden
- Lunds Universitet
- Gunnar Nilssons Cancerstiftelse
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet
- Fru Berta Kamprads Stiftelse
- Institut National Du Cancer
- Centralsjukhuset Kristianstad
- Region Skåne
- Skånes universitetssjukhus
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- breast cancer, driver mutations, RNA sequencing, prognostic and predictive biomarkers, precision oncology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. https://app.cochat.ai/papers/10.1186/s13073-015-0131-9
- The paper
- Saal, L. H., Vallon-Christersson, J., Häkkinen, J., Hegardt, C., Grabau, D., Winter, C., Brueffer, C., Tang, M.-H. E., Reuterswärd, C., Schulz, R., Karlsson, A., Ehinger, A., Malina, J., Manjer, J., Malmberg, M., Larsson, C., Rydén, L., Loman, N., & Borg, Å. (2015). The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Medicine. https://doi.org/10.1186/s13073-015-0131-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.